Stock Events

Stock Events

Damora Therapeutics 

$24.89
35
-$1.04-4.03% Tuesday 19:54

Statistics

Day High
25.96
Day Low
24.77
52W High
38.33
52W Low
2.35
Volume
141,826
Avg. Volume
-
Mkt Cap
33.03M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

5AugExpected
Q3 2025
Q4 2025
Next
Next
-3.24
-1.86
-0.48
0.9
Expected EPS
-0.378908
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-42.88MNet Income

Analyst Ratings

43.4Average Price Target
The highest estimate is 46.00.
From 5 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow DMRA. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Madrigal Pharmaceuticals
MDGL
Mkt Cap11.84B
Madrigal Pharmaceuticals is involved in developing therapies for fibrosis, particularly NASH, a direct area of competition with Galecto.
Galapagos NV
GLPG
Mkt Cap1.88B
Galapagos NV specializes in drug discovery for fibrosis and other indications, overlapping with Galecto's research areas.
ProQR Therapeutics N.V
PRQR
Mkt Cap163.31M
ProQR Therapeutics works on treatments for fibrosis among other diseases, positioning it as a competitor in the fibrosis space.
Gilead Sciences
GILD
Mkt Cap163.4B
Gilead Sciences has a strong portfolio in treating fibrotic diseases, making it a major competitor to Galecto.
Vertex Pharmaceuticals
VRTX
Mkt Cap107.83B
Vertex Pharmaceuticals has expanded its focus to include fibrosis, directly competing with Galecto's pipeline.
Pfizer
PFE
Mkt Cap149.77B
Pfizer has a broad range of treatments including for fibrosis, positioning it as a competitor across multiple areas including those targeted by Galecto.
Abbvie
ABBV
Mkt Cap365.43B
AbbVie has research interests in fibrosis, making it a competitor in the therapeutic area Galecto is targeting.
Novartis
NVS
Mkt Cap279.67B
Novartis has a diversified portfolio that includes treatments for fibrosis, competing with Galecto in the fibrosis therapeutic area.

About

Galecto, Inc. is a clinical-stage biotechnology company, which engages in developing novel small molecule therapeutics that are designed to target the biological processes that lie at the heart of cancer and fibrotic diseases. The firm is also involved in the development of small molecule inhibitors of galectin-3 and LOXL2. The company was founded by Ulf Jörgen Nilsson, Hakon Leffler, Tariq Sethi, and Hans Thalsgård Schambye in 2011 and is headquartered in Boston, MA.
Show more...
CEO
Ms. Lori C. Firmani
Employees
7
Country
United States
ISIN
US36322Q2066

Listings

XNAS
US
GLTO
BOATS
BOATS
GLTO.BOATS
XNAS
US
DMRA

0 Comments

Share your thoughts

FAQ

What is Damora Therapeutics stock price today?▼
The current price of DMRA is $24.89 USD — it has decreased by -4.03% in the past 24 hours. Watch Damora Therapeutics stock price performance more closely on the chart.
What is Damora Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Damora Therapeutics stocks are traded under the ticker DMRA.
What is Damora Therapeutics market cap?▼
Today Damora Therapeutics has the market capitalization of 33.03M
When is the next Damora Therapeutics earnings date?▼
Damora Therapeutics is going to release the next earnings report on August 05, 2026.
What is Damora Therapeutics revenue for the last year?▼
Damora Therapeutics revenue for the last year amounts to 0 USD.
What is Damora Therapeutics net income for the last year?▼
DMRA net income for the last year is -42.88M USD.
How many employees does Damora Therapeutics have?▼
As of May 06, 2026, the company has 7 employees.
In which sector is Damora Therapeutics located?▼
Damora Therapeutics operates in the Other sector.
When did Damora Therapeutics complete a stock split?▼
Damora Therapeutics has not had any recent stock splits.
Where is Damora Therapeutics headquartered?▼
Damora Therapeutics is headquartered in Waltham, United States.